Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
Bella Kaufman(NYU Langone Health), Susan M. Domchek(University City Science Center), Georgeta Fried(Sheba Medical Center), Michael Friedländer(Prince of Wales Hospital), Ronnie Shapira‐Frommer(Sheba Medical Center), M. William Audeh(Sheba Medical Center), Anitra Fielding(AstraZeneca (United States)), Judith Balmañà(Vall d'Hebron Hospital Universitari), Niklas Loman(Lund University), Gillian Mitchell(Peter MacCallum Cancer Centre), Mariana Steiner(Sheba Medical Center), Ayala Hubert(Sheba Medical Center), Karin Bowen(Sheba Medical Center), Ora Rosengarten(Sheba Medical Center), Rita K. Schmutzler(University of Cologne), Salomon M. Stemmer(Tel Aviv University)
Cited by 1,678
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k